Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

[1]  Matthew D. Zimmerman,et al.  The association between sterilizing activity and drug distribution into tuberculosis lesions , 2015, Nature Medicine.

[2]  A. Spanevello,et al.  New anti-tuberculosis drugs and regimens: 2015 update , 2015, ERJ Open Research.

[3]  M. Gurumurthy,et al.  Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis , 2014, PloS one.

[4]  M. Voskuil,et al.  Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas , 2014, Antimicrobial Agents and Chemotherapy.

[5]  B. Meibohm,et al.  Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux , 2014, Nature Medicine.

[6]  V. Dartois,et al.  A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. , 2013, Bioorganic & medicinal chemistry letters.

[7]  E. J. North,et al.  Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. , 2013, Bioorganic & medicinal chemistry.

[8]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[9]  W. Denny,et al.  Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2012, Journal of medicinal chemistry.

[10]  P. Niyomrattanakit,et al.  Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). , 2011, Journal of medicinal chemistry.

[11]  W. Denny,et al.  Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824) , 2010 .

[12]  W. Denny,et al.  Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2010, Journal of medicinal chemistry.

[13]  P. Niyomrattanakit,et al.  Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. , 2009, Journal of medicinal chemistry.

[14]  W. Denny,et al.  Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2009, Journal of medicinal chemistry.

[15]  Dianqing Sun,et al.  Synthesis, optimization and structure-activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. , 2009, European journal of medicinal chemistry.

[16]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[17]  B. Meibohm,et al.  A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. , 2008, The Journal of antimicrobial chemotherapy.

[18]  C. Lipinski,et al.  Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. , 2008, Bioorganic & medicinal chemistry letters.

[19]  Robert C. Reynolds,et al.  Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models , 2005, Antimicrobial Agents and Chemotherapy.

[20]  D. Menzies,et al.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[21]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.